High-dose therapy (HDT) and stem cell transplantation (SCT) has been in widespread use in the treatment of Hodgkin (HL) and non-Hodgkin lymphomas (NHLs) for more than 20 years. Despite this, the impact of this treatment on remission duration and overall survival for patients with these diseases remains poorly defined. High-dose therapy with autologous stem cell transplantation (ASCT) is now regarded as the standard of care for certain patients with relapsed and refractory HL or relapsed aggressive B cell NHL. This is supported by results from prospective, randomized clinical trials. The role of HDT and ASCT as a component of first-line therapy for certain ‘high risk’ patients with HL and NHL is also being better defined as results emerge from recently completed randomized studies.
ASJC Scopus subject areas